The effect of finasteride in the prevention of bladder tumor recurrence

The effect of finasteride (compared to placebo) in preventing recurrence in patients with bladder tumor

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200608047702N1

Enrollment

124

Registered

2021-12-25

Start date

2021-06-05

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer. Malignant neoplasm of bladder, unspecified

Interventions

Intervention 1: Intervention group: Finasteride ( Daru Pakhsh CO. Tehran, Iran) receive 5 mg /day and complications and response to treatment are evaluated every three months. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with bladder tumors, which are candidates of fallow up Consent to inclusion the study insensitivity to drug Patient cooperation during the study Age 18 to 70 years

Exclusion criteria

Exclusion criteria: No consent to the inclusion of the study Loss of patient in f/u No regular drug use Patients with underlying disease

Design outcomes

Primary

Measure	Time frame
Prevention of recurrence of bladder cancer. Timepoint: before intervention and every 3 months for a period of one year. Method of measurement: cystoscopy pathology report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactalireza farshi

Tabriz University of Medical Sciences

dr.ramezanireza70@gmail.com+98 41 3337 6923

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026